Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Oct;33(10):1778–1782. doi: 10.1128/aac.33.10.1778

Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.

W R Bowie 1, V Willetts 1, P J Jewesson 1
PMCID: PMC172754  PMID: 2511802

Abstract

New fluoroquinolones have generally been well tolerated. In a double-blind evaluation of oral fleroxacin, using 400, 600, or 800 mg once daily for 7 days in an ambulatory setting for treatment of uncomplicated genital infections, we encountered unexpectedly high rates of adverse reactions. The objective of this analysis was to determine whether any factors in addition to dose could be found to account for our observations. Adverse reactions developed in 66 (84%) of 79 individuals, and severe reactions arose in 38 (48%). Most frequent were central nervous system reactions (70%), with insomnia being especially frequent (49%); gastrointestinal reactions (39%) and photosensitivity reactions (10%) were also common. Development of any reaction (central nervous system reactions, insomnia, and severe intestinal reactions) was dose related. Development of photosensitivity reactions correlated with an outdoor occupation. No other factors, including usual daily caffeine use, correlated with the development of adverse reactions. In our study, fleroxacin taken as a single daily 600- or 800-mg dose was associated with an unacceptably high rate of adverse reactions. Other studies are required to determine whether this problem is unique to fleroxacin or will occur with higher doses of other fluoroquinolones possessing similar chemical modifications and/or good tissue penetration and very long half-lives.

Full text

PDF
1778

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arcieri G., August R., Becker N., Doyle C., Griffith E., Gruenwaldt G., Heyd A., O'Brien B. Clinical experience with ciprofloxacin in the USA. Eur J Clin Microbiol. 1986 Apr;5(2):220–225. doi: 10.1007/BF02013994. [DOI] [PubMed] [Google Scholar]
  2. Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):187–193. doi: 10.1093/jac/18.sd.187. [DOI] [PubMed] [Google Scholar]
  3. Bowie W. R., Willetts V., Megran D. W. Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections. Antimicrob Agents Chemother. 1989 Oct;33(10):1774–1777. doi: 10.1128/aac.33.10.1774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bowie W. R., Willetts V., Sibau L. Failure of norfloxacin to eradicate Chlamydia trachomatis in nongonococcal urethritis. Antimicrob Agents Chemother. 1986 Oct;30(4):594–597. doi: 10.1128/aac.30.4.594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davey P. G. Overview of drug interactions with the quinolones. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):97–107. doi: 10.1093/jac/22.supplement_c.97. [DOI] [PubMed] [Google Scholar]
  6. Griggs D. J., Wise R., Kirkpatrick B., Ashby J. P. The metabolism and pharmacokinetics of fleroxacin in healthy subjects. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):191–194. doi: 10.1093/jac/22.supplement_d.191. [DOI] [PubMed] [Google Scholar]
  7. Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S258–S261. doi: 10.1093/clinids/10.supplement_1.s258. [DOI] [PubMed] [Google Scholar]
  8. Handsfield H. H., Judson F. N., Holmes K. K. Treatment of uncomplicated gonorrhea with rosoxacin. Antimicrob Agents Chemother. 1981 Nov;20(5):625–629. doi: 10.1128/aac.20.5.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jensen T., Pedersen S. S., Nielsen C. H., Høiby N., Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother. 1987 Oct;20(4):585–594. doi: 10.1093/jac/20.4.585. [DOI] [PubMed] [Google Scholar]
  11. Jüngst G., Mohr R. Overview of postmarketing experience with ofloxacin in Germany. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):167–175. doi: 10.1093/jac/22.supplement_c.167. [DOI] [PubMed] [Google Scholar]
  12. Mayrer A. R., Andriole V. T. Urinary tract antiseptics. Med Clin North Am. 1982 Jan;66(1):199–208. doi: 10.1016/s0025-7125(16)31453-5. [DOI] [PubMed] [Google Scholar]
  13. Pust R. A., Ackenheil-Köppe H. R., Weidner W., Meier-Ewert H. Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):227–230. doi: 10.1093/jac/22.supplement_d.227. [DOI] [PubMed] [Google Scholar]
  14. Sanders W. E., Jr Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis. 1988 May-Jun;10(3):528–543. doi: 10.1093/clinids/10.3.528. [DOI] [PubMed] [Google Scholar]
  15. Shah P. M., Sammann A., Schäfer V., Seczendi M., Knothe H. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):209–213. doi: 10.1093/jac/22.supplement_d.209. [DOI] [PubMed] [Google Scholar]
  16. Sorgel F., Metz R., Naber K., Seelmann R., Muth P. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):155–167. doi: 10.1093/jac/22.supplement_d.155. [DOI] [PubMed] [Google Scholar]
  17. Sörgel F., Seelmann R., Naber K., Metz R., Muth P. Metabolism of fleroxacin in man. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):169–178. doi: 10.1093/jac/22.supplement_d.169. [DOI] [PubMed] [Google Scholar]
  18. Weidekamm E., Portmann R., Partos C., Dell D. Single and multiple dose pharmacokinetics of fleroxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):145–154. doi: 10.1093/jac/22.supplement_d.145. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES